News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Here's Why Pfizer Inc. (PFE) Should Buy GlaxoSmithKline (GSK)


7/9/2014 8:11:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In the aftermath of pharmaceutical giant Pfizer (NYSE: PFE ) failing in its repeated attempts to acquire European drug maker AstraZeneca (NYSE: AZN ) , investors may be wondering what's next. After all, Pfizer's enormous offer and seeming willingness to pay quite a premium to no avail has left a bit of egg on management's face. In its post-Lipitor era, organic growth has been hard to come by. And, since taking new drugs all the way to market is an extremely costly and time-consuming effort, management probably feels the easiest way to get the growth it needs now is by buying up a rival company.

Hey, check out all the research scientist jobs. Post your resume today!

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES